MAPT and Alzheimer disease: However, currently established AD biomarkers for clinical use either require an invasive procedure (cerebrospinal fluid analysis), or are associated with high costs and limited availability, such as amyloid positron emission tomography (PET) and tau-PET scans, so they cannot be applied to a large populationsample worldwide, especially with repeated measures.